InVivo Therapeutics enrolled another patient in its INSPIRE Study, testing the Neuro-Spinal Scaffold's efficacy and safety for complete thoracic AIS A spinal cord injury.
Here are four notes:
1. James Harrop, MD, and Josh Heller, MD, of Philadelphia-based Thomas Jefferson University Hospital, implanted the device in the patient about 22 hours after injury.
2. Dr. Heller serves as the site's principal investigator.
3. The INSPIRE Study now includes 17 enrolled patients in follow up.
4. Mark Perrin, InVivo's CEO and chairman, said he is hopeful they will complete INSPIRE enrollment during the third quarter of 2017.